# Body Vision Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/body-vision-medical

- Industry: Medical Devices & Equipment
- Headquarters: Ramat HaSharon, Israel
- Website: www.bodyvisionmedical.com
- Latest round: Series B (Jul 1, 2018)
- Investors on record: 1

## About

Body Vision Medical LTD specializes in advanced AI-driven imaging solutions for lung cancer diagnostics and therapies, enhancing the precision of medical interventions through innovative technologies.Body Vision Medical LTD, founded in 2014, is headquartered in Ramat HaSharon, Israel. The company focuses on developing AI-driven imaging solutions to improve lung cancer diagnostics and therapies. Dorian Averbuch, the founder, has a history of innovation in the medical technology sector. Since its inception, Body Vision Medical has completed three funding deals, with the most recent being a Series C round in September 2019 that raised USD 20.00 mn, bringing the total amount raised to USD 20.00 mn.Body Vision Medical specializes in advanced AI-driven imaging solutions designed for lung cancer diagnostics and therapies. Its flagship product, LungVision®, utilizes proprietary AI Tomo® technology to transform standard 2D C-arm systems into sophisticated 3D imaging platforms capable of real-time navigation for biopsies and localized treatments of pulmonary nodules. This technology addresses critical challenges in acquiring diagnostic tissue samples, particularly in overcoming CT-to-Body divergence, which can hinder accurate lesion location during procedures. The company’s solutions are primarily targeted at healthcare professionals, including pulmonologists and thoracic surgeons, enhancing their ability to detect and treat lung cancer with increased precision and confidence. Body Vision Medical serves a global client base, with products utilized in healthcare facilities across the United States, Europe, and other international markets.Body Vision Medical generates revenue through direct sales of its high-precision imaging systems and associated services to healthcare institutions. The transaction model is primarily B2B, where hospitals and medical centers purchase the LungVision® system as part of their interventional pulmonology offerings. Clients may also engage in partnerships for ongoing support, training, and maintenance services post-purchase. The pricing structure for these systems is built on a combination of upfront capital expenditure for the equipment and recurring revenues from associated service contracts. By providing advanced imaging technology that significantly improves diagnostic yield rates, the company aligns its value proposition with the operational needs of healthcare providers, facilitating more effective lung cancer interventions.Body Vision Medical plans to leverage its recent Series C funding of USD 20.00 mn, raised in September 2019, to support the development of new products and to expand into new markets. The company is focusing on launching enhanced versions of LungVision® with capabilities for broader diagnostic applications, aiming for release in the next 12 to 18 months. Additionally, Body Vision Medical is targeting expansion into Asian and Latin American markets by 2025, providing access to its innovative imaging solutions to a larger global audience.

## Funding rounds

- Series B, Jul 1, 2018 — Champel Capital

## Investors

- Champel Capital (https://capitalatlas.ai/funds/champel-capital) — Series B